BACKGROUND: No investigation of amrubicin monotherapy in pre-treated advanced non-small cell lung cancer (NSCLC) patients has yet been reported. PATIENTS AND METHODS: The records were reviewed of NSCLC patients who had received amrubicin monotherapy between 2003 and 2007 with the following eligibility criteria:previously treated with at least two regimens including platinum and docetaxel for non-adenocarcinoma patients and platinum, docetaxel and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) for adenocarcinoma patients. Amrubicin was administered to both groups at 35 mg/m2 or 40 mg/m2 for 3 consecutive days, every 3 weeks. RESULTS: Thirty-nine patients were registered. The median number of prior chemotherapy regimens was three (range: 2 to 7). The median number of courses per patient was three (range one to 9). The toxicity profile was acceptable with no grade 3 or higher non-hematological toxicity. The overall response rate was 10.2%. The median survival time was 4.8 months. CONCLUSION: Amrubicin exhibits activity and acceptable toxicity as third or subsequent line of chemotherapy for advanced NSCLC.
BACKGROUND: No investigation of amrubicin monotherapy in pre-treated advanced non-small cell lung cancer (NSCLC) patients has yet been reported. PATIENTS AND METHODS: The records were reviewed of NSCLCpatients who had received amrubicin monotherapy between 2003 and 2007 with the following eligibility criteria:previously treated with at least two regimens including platinum and docetaxel for non-adenocarcinomapatients and platinum, docetaxel and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) for adenocarcinomapatients. Amrubicin was administered to both groups at 35 mg/m2 or 40 mg/m2 for 3 consecutive days, every 3 weeks. RESULTS: Thirty-nine patients were registered. The median number of prior chemotherapy regimens was three (range: 2 to 7). The median number of courses per patient was three (range one to 9). The toxicity profile was acceptable with no grade 3 or higher non-hematological toxicity. The overall response rate was 10.2%. The median survival time was 4.8 months. CONCLUSION:Amrubicin exhibits activity and acceptable toxicity as third or subsequent line of chemotherapy for advanced NSCLC.
Authors: Rachael E Hawtin; David E Stockett; Jo Ann W Byl; Robert S McDowell; Tan Nguyen; Michelle R Arkin; Andrew Conroy; Wenjin Yang; Neil Osheroff; Judith A Fox Journal: PLoS One Date: 2010-04-15 Impact factor: 3.240